CDNS vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 07, 2026

CDNS

30.6
AI Score
VS
MRNA Wins

MRNA

37.1
AI Score

Investment Advisor Scores

CDNS

31score
Recommendation
AVOID NEW MONEY

MRNA

37score
Recommendation
EXTENDED

AI Analyst Insights

Detailed Metrics Comparison

Metric CDNS MRNA Winner
Forward P/E 31.5457 23.0415 MRNA
PEG Ratio 2.3143 0 Tie
Revenue Growth 24.2% 2.1% CDNS
Earnings Growth 125.4% -85.1% CDNS
Tradestie Score 30.6/100 37.1/100 MRNA
Profit Margin 23.6% -141.4% CDNS
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY EXTENDED MRNA

Relative Price Performance (Last 90 Days)

CDNS 1M: +25.3% · 3M: -7.7% MRNA 1M: +40.0% · 3M: +156.6%

Current Technical Phase

CDNS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 70

RSI (14): 70.5 · Price: $356.12

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

Fundamentals Snapshot

Metric CDNS MRNA
Market Cap — —
Forward P/E 37.2 -41.0
Trailing P/E 70.2 —
Revenue (TTM) — —
Revenue Growth 0.2% 0.0%
Gross Margin 0.9% -0.7%
Operating Margin 0.3% -5.6%
EPS 5.12 -7.36
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.